TY  - CHAP
M1  - Book, Section
TI  - Clopidogrel Pharmacogenomics
A1  - Chyou, Janice Y.
A1  - Sabatine, Marc S.
A2  - Murray, Michael F.
A2  - Babyatsky, Mark W.
A2  - Giovanni, Monica A.
A2  - Alkuraya, Fowzan S.
A2  - Stewart, Douglas R.
PY  - 2014
T2  - Clinical Genomics: Practical Applications in Adult Patient Care
AB  - Drug  summary:Clopidogrel  blocks  the  P2Y12  adenosine  diphosphate  (ADP)  receptor  on  the  surface  of  platelets  and  thus  inhibits  platelet  activation.Despite  established  clinical  efficacy,  an  inadequate  response  to  clopidogrel  has  been  observed  in  up  to  30%  of  compliant  patients.  Such  variability  has  been  labeled  as  “clopidogrel  nonresponsiveness,”  “clopidogrel  hyporesponsiveness,”  and  “clopidogrel  resistance.”  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessbiomedicalscience.mhmedical.com/content.aspx?aid=1102698579
ER  -